Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents

Gene Therapy

Volumn 20, Issue 3, 2013, Pages 262-273

  Jarosz, M ^a   Jazowiecka Rakus, J ^a   Cichon T ^a   Glowala Kosinska M ^a   Smolarczyk, R ^a   Smagur, A ^a   Malina, S ^a   Sochanik, A ^a   Szala, S ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; DNA VACCINE; ENDOGLIN; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENSITY; ENDOTHELIUM CELL; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; INOCULATION; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SALMONELLA TYPHIMURIUM; T LYMPHOCYTE ACTIVATION; VACCINATION; WOUND HEALING;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; COS CELLS; CYCLOPHOSPHAMIDE; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; GENETIC THERAPY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-12; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; SALMONELLA TYPHIMURIUM; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; VACCINES, DNA;

ANIMALIA; MUS; SALMONELLA TYPHIMURIUM;

EID: 84874771064     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.28     Document Type: Article

References (71)

1. Tabi Z, Man S. Challenges for cancer vaccine development. Adv Drug Deliv Rev 2006; 58: 902-915.
2. Hofmeister V, Vetter C, Schrama D, Brocker E-B, Becker JC. Tumor stromaassociated antigens for anti-cancer immunotherapy. Cancer Immunol Immunother 2006; 55: 481-494.
3. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010; 46: 1323-1332.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
5. Ebos JML, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210-221.
6. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010; 1: 12-25.
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
8. Dome B, Hendrix MJC, Paku S, Tó vá ri J, Ti'ma'r J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007; 170: 1-15.
9. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
10. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
11. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 2011; 108: 4274-4280.
12. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
13. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
14. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011; 108: 3749-3754.
15. Szala S, Mitrus I, Sochanik A. Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy? Cancer Immunol Immunother 2010; 59: 1449-1455.
16. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004; 53: 844-854.
17. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66: 5527-5536.
18. Disis ML. Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment. Clin Cancer Res 2009; 15: 6476-6478.
19. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18: 11-18.
20. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-1375.
21. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17: 984-992.
22. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937.
23. Fonsatti E, Nicolay HJM, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-19.
24. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 2010; 30: 334-345.
25. Romero D, O'Neill C, Terzic A, Contois L, Young K, Conley BA et al. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Res 2011; 71: 3482-3493.
26. Stocker BAD. Aromatic-dependent Salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them. J Biotechnol 2000; 83: 45-50.
27. Darji A, Guzma'n CA, Gerstel B, Wachholz P, Timmis KN, Wehland J et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997; 91: 765-775.
28. Reisfeld RA, Niethammer AG, Luo Y, Xiang R. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev 2004; 199: 181-190.
29. Lee S-H, Mizutani N, Mizutani M, Luo Y, Zhou H, Kaplan C et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 2006; 55: 1565-1574.
30. Jiao J-G, Li Y-N, Wang H, Liu Q, Cao J-X, Bai R-Z et al. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis 2006; 38: 578-587.
31. Feng K-K, Zhao H-Y, Qiu H, Liu J-X, Chen J. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects. Cancer Lett 2005; 221: 41-47.
32. Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 2005; 65: 5027-5030.
33. Portielje JEA, Gratama JW, van Ojik HH, Stoter G, Kruit WHJ. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 2003; 52: 133-144.
34. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685.
35. Uemura A, Takehara T, Miyagi T, Suzuki T, Tatsumi T, Ohkawa K et al. Natural killer cell is a major producer of interferon c that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother 2010; 59: 453-463.
36. Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumorassociated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006; 177: 6962-6973.
37. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.
38. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
39. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
40. Matejuk A, Leng Q, Chou S-T, Mixson AJ. Vaccines targeting the neovasculature of tumors. Vasc Cell 2011; 3: 7.
41. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004; 95: 85-90.
42. Gardlik R, Behuliak M, Palffy R, Celec P, Li CJ. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Therapy 2011; 18: 425-431.
43. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92: 3172-3176.
44. Luo Y, Zhou H, Mizutani M, Mizutani N, Liu C, Xiang R et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res 2005; 65: 3419-3427.
45. Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y et al. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 2004; 112: 701-706.
46. Tan G-H, Li Y-N, Huang F-Y, Wang H, Bai R-Z, Jang J. Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects. Immunol Invest 2007; 36: 423-440.
47. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H et al. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 2008; 122: 2266-2273.
48. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009; 125: 1446-1453.
49. Paglia P, Terrazzini N, Schulze K, Guzma'n CA, Colombo MP. In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Therapy 2000; 7: 1725-1730.
50. Sirard J-C, Niedergang F, Kraehenbuhl J-P. Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol Rev 1999; 171: 5-26.
51. Tascon RE, Ragno S, Lowrie DB, Colston MJ. Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+ T cells. Immunology 2000; 99: 1-7.
52. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010: 174378.
53. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001; 98: 3299-3303.
54. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
55. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008; 11: 79-89.
56. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002; 21: 8272-8281.
57. Wong VC, Chan PL, Bernabeu C, Law S, Wang LD, Li JL et al. Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer 2008; 123: 2816-2823.
58. Henry LA, Johnson DA, Sarrió D, Lee S, Quinlan PR, Crook T et al. Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene 2011; 30: 1046-1058.
59. Pe'rez-Go'mez E, Del Castillo G, Juan Francisco S, Lo'pez-Novoa JM, Bernabe'u C, Quintanilla M. The role of the TGF-b coreceptor endoglin in cancer. ScientificWorldJournal 2010; 10: 2367-2384.
60. Zhang Y, Yang Y, Hong H, Cai W. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med 2011; 4: 32-42.
61. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 2007; 25: 376-383.
62. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
63. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8: 393-404.
64. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003; 116: 2677-2685.
65. Dickerson EB, Akhtar N, Steinberg H, Wang Z-Y, Lindstrom MJ, Padilla ML et al. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to avb3 integrin. Mol Cancer Res 2004; 2: 663-673.
66. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
67. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
68. Michael A, Stratford R, Khan S, Dalgleish A, Pandha H. Novel strains of Salmonella typhimurium as potential vectors for gene delivery. FEMS Microbiol Lett 2004; 238: 345-351.
69. Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005; 65: 553-561.
70. Kaplan CD, Kruger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine 2006; 24: 6994-7002.
71. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-1962.